About lenvatinib mesilate
Tyrosine kinase inhibitor
Used for
- Treats certain thyroid cancers that no longer respond to radioactive iodine.
- Treats advanced kidney cancer, often with pembrolizumab or everolimus.
- Treats unresectable liver cancer.
- Treats advanced endometrial cancer with pembrolizumab.
Usual adult dose
Usually 24 mg once daily for thyroid or endometrial cancer; 8–12 mg once daily for liver cancer, based on body weight. Kidney cancer dosing depends on combination.
Common side effects
- High blood pressure
- Diarrhea, nausea, or reduced appetite
- Tiredness
- Protein in urine
Important warnings
- May cause serious bleeding, blood clots, heart problems, or kidney or liver injury.
- Can cause severe diarrhea, dehydration, or gastrointestinal perforation.
- May impair wound healing; treatment may need to stop before surgery.
- Monitor blood pressure, urine protein, thyroid function, and kidney and liver tests.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for at least 30 days afterward.
Breastfeeding
Do not breastfeed during treatment and for at least one week after the last dose.
Interactions
- Some medicines that affect CYP3A or P-glycoprotein can alter lenvatinib levels.
- Medicines that prolong the QT interval may increase heart rhythm risks.
- Other treatments that raise bleeding or blood pressure risks may worsen side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.